Boehringer Ingelheim is pumping 30 million euros ($31 million) into the fight against drug-resistant bacteria. Working with Evotec and bioMérieux, the German drugmaker has set up Aurobac Therapeutics, a biotech that will take a precision medicine approach to diagnosing and treating infections.
Antimicrobial resistance (AMR) is threatening to undo decades of healthcare progress, with one forecast suggesting it could cause 10 million deaths a year by 2050.